On Tuesday, Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX) ...

Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.

Fintel reports that on March 1, 2024, B of A Securities upgraded their outlook for Vertex (NasdaqGM:VERX) from Underperform to Neutral. As of February 24, 2024, the average one-year price target for ...

In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Vertex (VERX – Research Report), with a price target of $47.00. The company’s shares closed yesterday at ...

Q4 2025 earnings call highlights: 2026 revenue outlook, ALYFTREK progress, CASGEVY/JOURNAVX growth, and renal pipeline—read ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $438.40.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener An update from ...